IRIS
Russo, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.324
AS - Asia 2.152
SA - Sud America 1.050
EU - Europa 518
Continente sconosciuto - Info sul continente non disponibili 189
AF - Africa 66
OC - Oceania 3
Totale 7.302
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.175
SG - Singapore 981
BR - Brasile 800
VN - Vietnam 630
CN - Cina 265
IT - Italia 247
DE - Germania 119
AR - Argentina 109
CA - Canada 68
EC - Ecuador 53
ID - Indonesia 53
BD - Bangladesh 45
HK - Hong Kong 44
GB - Regno Unito 38
MX - Messico 38
FR - Francia 30
IN - India 30
PY - Paraguay 25
CO - Colombia 22
IQ - Iraq 19
PL - Polonia 17
ZA - Sudafrica 17
CL - Cile 15
PK - Pakistan 13
RU - Federazione Russa 12
CR - Costa Rica 10
MA - Marocco 9
PE - Perù 9
TN - Tunisia 9
UA - Ucraina 9
AT - Austria 8
DZ - Algeria 8
EG - Egitto 8
JP - Giappone 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
ES - Italia 7
JM - Giamaica 7
VE - Venezuela 7
FI - Finlandia 6
JO - Giordania 6
KE - Kenya 6
KZ - Kazakistan 6
TR - Turchia 6
UZ - Uzbekistan 6
HN - Honduras 5
MY - Malesia 5
KG - Kirghizistan 4
NL - Olanda 4
PH - Filippine 4
SE - Svezia 4
GE - Georgia 3
KW - Kuwait 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
ET - Etiopia 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
IE - Irlanda 2
KR - Corea 2
LC - Santa Lucia 2
NG - Nigeria 2
SA - Arabia Saudita 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AO - Angola 1
BH - Bahrain 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GH - Ghana 1
GN - Guinea 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 7.115
Salva come PNG Salva come JPEG
Città #
Dallas 864
Ashburn 265
Singapore 263
Ho Chi Minh City 241
San Jose 217
Council Bluffs 190
Hanoi 148
Beijing 129
Falkenstein 105
Santa Clara 84
Los Angeles 77
Milan 74
São Paulo 66
New York 65
Hong Kong 44
Rome 43
Rio de Janeiro 35
Buffalo 32
Phoenix 31
Orem 29
Haiphong 24
Guayaquil 23
Princeton 22
Assago 20
Biên Hòa 19
Brooklyn 19
Philadelphia 19
Curitiba 17
Da Nang 17
Mexico City 17
Chicago 16
Houston 16
Warsaw 16
Charlotte 15
Montreal 15
Naples 15
Las Vegas 14
Toronto 14
Atlanta 13
Quito 13
Asunción 12
Brasília 12
Hải Dương 12
London 12
Porto Alegre 12
Ninh Bình 11
Austin 10
Buenos Aires 10
Figino 10
Laurinburg 10
Lấp Vò 10
Manaus 10
Richmond 10
Salvador 10
Turin 10
Campinas 9
Chennai 9
Denver 9
Dhaka 9
Ha Long 9
Thái Bình 9
Bogotá 8
Guarulhos 8
Jundiaí 8
Osasco 8
Abbeville 7
Belo Horizonte 7
Cape Town 7
Fortaleza 7
Johannesburg 7
Maceió 7
New Braunfels 7
Nova Iguaçu 7
Amman 6
Boston 6
Caracas 6
Columbia 6
Helsinki 6
Jakarta 6
Lahore 6
Louisville 6
Manchester 6
Miami 6
Milwaukee 6
Mumbai 6
Okmulgee 6
Pasadena 6
Queens 6
San José 6
Santiago 6
Santo André 6
Sumaré 6
Tampa 6
Tashkent 6
Tokyo 6
Washington 6
Bauru 5
Blumenau 5
Cincinnati 5
Córdoba 5
Totale 3.807
Salva come PNG Salva come JPEG
Nome #
117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients. 578
Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer 78
Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology. 73
New strategies to overcome BRAF resistance in melanoma: extended BRAF or BRAF/MEK inhibition? A pooled analysis. 73
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 72
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database 71
Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 71
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. 70
31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients 69
Baseline Absolute Neutrophil Count (ANC), derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Platelet-to-Lymphocyte Ratio (PLR) and outcome in Non Small Cell Lung Cancer (NSCLC) treated with Nivolumab or Docetaxel: a preliminary analysis. 66
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 66
Impact of maintenance Pemetrexed in the management of non-progressing malignant mesotheliomas after standard fist-line chemotherapy: a single institution experience. 64
Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis. 63
55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicenter study. 62
Impact of germline Methylenetetrahydrofolate Reductase (MTHFR) polymorphisms on Pemetrexed-based therapies In thoracic malignancies: a pilot study. 60
Treatment Toxicity 58
Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met? 58
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 58
Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis. 57
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance 57
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non small cell lung cancer (NSCLC) 57
The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis 56
Exosomal PD-L1 expression as non-invasive biomarker for immune checkpoint inhibitors in non-small cell lung cancer. 55
The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis. 55
PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients. 55
Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study 53
HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target. 53
Immune-Oncology Gene Expression Profiles allow lung cancer patients' stratification and identification of responders to immunotherapy. 52
Activity of EGFR tyrosine kinase inhibitors (TKIs) in brain metastases from Non Small Cell Lung Cancer (NSCLC) according to the EGFR mutational status: a survival analysis. 52
Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers. 51
Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study 51
How I treat ALK-positive non-small cell lung cancer 50
Baseline markers of inflammation and outcome with Nivolumab in pretreated Non Small Cell Lung Cancers: a retrospective study. 50
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 50
A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection 49
Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy 48
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 48
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 48
KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. 46
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 46
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 45
Brave new world of cfDNA-omics for early cancer detection. 45
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study 44
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 43
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 43
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities 43
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer 42
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. 42
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer 42
Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care? 42
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 41
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study 41
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP. 41
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. 41
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. 40
Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19 40
A New Generation of Vaccines in the Age of Immunotherapy. 40
Game-Set-MATCH: Liquid Biopsy Advances to the Next Round 40
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA 40
A Potentially New Targetable Alteration for the Treatment of Lung Cancer 40
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. 40
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy. 39
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 39
Acquired resistance in oncogene-addicted non-small-cell lung cancer 39
Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients. 39
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer. 39
Application of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 39
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types 38
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 38
Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non-Small-Cell Lung Cancer 38
Liquid Biopsy from research to clinical practice: focus on Non-Small Cell Lung Cancer. 38
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. 38
Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies 37
Innovation in next-generation sequencing in non-small cell lung cancer diagnostics 37
Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives 37
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer? 37
Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung. 37
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 36
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 36
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). 36
Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer 36
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients. 36
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer 36
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. 36
Challenges of interpreting NGS liquid biopsy (LB) results in advanced NSCLC: Are ESCAT and OncoKB scales reliable? 36
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. 36
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 35
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) 35
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 35
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 35
Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing. 35
NSCLC and HER2: between lights and shadows 35
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 34
Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes. 34
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 34
Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review. 33
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. 33
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question 33
Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities. A commentary of the 3-year follow-up of the KEYNOTE-001 trial 33
Tracking clonal evolution of EGFR-mutated non-small cell lung cancer through liquid biopsy: Management of C797S acquired mutation 33
Totale 5.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20243 0 0 0 0 0 0 0 1 0 0 1 1
2024/20259 1 0 0 0 0 1 1 0 2 3 1 0
2025/20265.518 147 446 1.153 1.119 415 207 566 468 254 229 220 294
2026/20271.772 479 288 792 213 0 0 0 0 0 0 0 0
Totale 7.302